220540-73-8

Upstream product

• 109-02-4 4-methyl-morpholine 
• 3140-73-6 2-chloro-4,6-dimethoxy-1 ,3,5-triazine 
• 159634-94-3 (R)-2-(2-tert-Butoxycarbonylamino-2-methyl-propionylamino)-3-(1H-indol-3-yl)-propionic acid 
• 123-75-1 pyrrolidine 
• 220541-31-1 ethyl 2-[4-((2R)-2-(2-[(tert-butoxy)carbonylamino]-2-methylpropanoylamino)-3-indol-3-ylpropanoylamino)imidazolyl]-2-phenylacetate 

Relevant academic research and scientific papers

Growth hormone secretagogues

What is disclosed are growth hormone secretagogues, and their uses, of the formula wherein R1 is C6H5CH2OCH2—, C6H5(CH2)3— or indol-3-ylmethyl; Y is pyrrolidin-1-yl, 4-C1-C6alkylpiperidin-1-yl or NR2R2; R2 are each independently a C1to C6alkyl; R3 is 2-napthyl or phenyl para-substituted by W; W is H, F, CF3, C1-C6alkoxy or phenyl; and R4 is H or CH3, or a pharmaceutically acceptable salt or solvate thereof.

Treatment of congestive heart failure with growth hormone secretagogues

The present invention is directed to methods for the modulation of cardiac function which comprise the administration of certain compounds, as defined herein, having growth hormone secretagogue activity.